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Abstract
Introduction Tamoxifen is a selective estrogen receptor
modulator widely used in the treatment of breast cancer.
Tamoxifen therapy is associated with lower circulating
low-density lipoprotein cholesterol and increased triglyc-
erides, but its effects on other lipids are less well studied.
Aims We aimed to investigate the effect of tamoxifen on
circulating concentrations of lipoprotein(a) [Lp(a)] through
a meta-analysis of available randomized controlled trials
(RCTs) and observational studies.
Methods This study was registered in the PROSPERO
database (CRD42016036890). Scopus, MEDLINE and
EMBASE were searched from inception until 22 March
2016 to identify studies investigating the effect of tamox-
ifen on Lp(a) values in humans. Meta-analysis was per-
formed using an inverse variance-weighted, random-effects
model with standardized mean difference (SMD) as the
effect size estimate.
Results Meta-analysis of five studies with 215 participants
suggested a statistically significant reduction of
Lp(a) levels following tamoxifen treatment (SMD -0.41,
95% confidence interval -0.68 to -0.14, p = 0.003). This
effect was robust in the sensitivity analysis.
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Conclusions Meta-analysis suggested a statistically sig-
nificant reduction of Lp(a) levels following tamoxifen
treatment. Further well-designed trials are required to
validate these results.
Key Points
Lipoprotein(a) [Lp(a)] is an emerging risk factor for
cardiovascular disease; it is relatively resistant to
reduction by dietary and pharmacological methods.
Tamoxifen, a selective estrogen receptor modulator,
is widely used in the treatment of breast cancer.
This meta-analysis demonstrates a significant
reduction of Lp(a) levels after tamoxifen treatment.
1 Introduction
Lipoprotein(a) [Lp(a)], first discovered by Kare Berg in
1963, is a low-density lipoprotein (LDL)-like particle
containing apolipoprotein(a) [apo(a)] and apolipoprotein
B-100 (apo-B100) linked through a disulfide bond [1]. It
has been shown that Lp(a) contributes to atherosclerosis
through accelerated transport of oxidized phospholipids [2]
and inhibition of fibrinolysis [3]. Plasma Lp(a) levels are
influenced by several factors such as genetic polymor-
phisms of apo(a) [4], sex, age, race [5, 6], smoking, alcohol
consumption, dietary habits, intense exercise, thyroid
function [7] and hormonal factors. However, Lp(a) appears
to be more resistant to drug and lifestyle interventions than
any other lipoprotein [8]. A continuous and independent
association between enhanced Lp(a) levels and risk of
coronary heart disease [9], ischemic stroke [10], venous
thromboembolism [11], aortic valve stenosis and aortic
valve calcification [12] has been observed. Many strategies
designed to target Lp(a) have been tested, including nico-
tinic acid [13–15], apheresis [16], the apo-B synthesis
inhibitor mipomersen [17, 18], inhibitors of proprotein
convertase subtilisin/kexin type 9 (PCSK9), coenzyme Q10
[19], cholesteryl ester transfer protein (CETP) inhibitors,
aspirin, the thyroid hormone analog eprotirome [20], and
synthetic inhibitors of microsomal triglyceride transfer
protein [21]. However, the benefit of these strategies in
clinical trials seems to be derived from effects on other
lipids [22].
Tamoxifen is a selective estrogen receptor modulator
(SERM), which has been used since 1977 for the treat-
ment of women with early or advanced stages of breast
tumors [23]. SERMS act as agonists of estrogen recep-
tors in some tissues and as antagonists in others [24],
hence their designation as ‘‘modulators’’ of estrogen
receptors rather than as ‘‘agonists’’ or ‘‘antagonists.’’ In
addition to its beneficial effects on cancer, it has been
suggested that tamoxifen may decrease the risk of car-
diovascular disease (CVD) and associated mortality by
modulating lipid metabolism [25–27]. In particular,
tamoxifen has been associated with a reduction in cir-
culating low-density lipoprotein-cholesterol (LDL-C)
[28]. However, tamoxifen was not shown to have any
benefit on cardiovascular risk in the Breast Cancer
Prevention trial [29]. Moreover, the Heart and Estrogen/
Progestin Replacement Study (HERS) showed that
treatment with estrogen plus progestin led to greater
CVD risk than placebo in a randomized controlled trial
(RCT) in high-risk patients [30]. It is thus important that
the effects of individual SERMS and estrogen receptor
ligands on lipid profiles and cardiovascular risk are
thoughtfully explored, rather than assuming a class effect
for these drugs [29].
Some experimental and clinical trials have reported an
important role of tamoxifen in decreasing lipids and
Lp(a) levels; however, the available evidence is contro-
versial and mostly inconclusive. Therefore, we aimed to
assess the impact of tamoxifen on plasma Lp(a) concen-
trations through a meta-analysis of available RCTs and
observational studies.
2 Methods
This study was designed according to the guidelines of the
2009 Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement [31] and was
registered in the Prospero database (CRD42016036890).
2.1 Search Strategy
Scopus (http://www.scopus.com), EMBASE (http://
www.embase.com) and MEDLINE (http://www.ncbi.
nlm.nih.gov/pubmed) databases were searched using the
following search terms in titles and abstracts: (‘‘lp(a)’’
OR ‘‘LP (a)’’ OR ‘‘lipoprotein(a)’’ OR ‘‘lipoprotein (a)’’)
AND (tamoxifen). The wild-card term ‘‘*’’ was used to
increase the sensitivity of the search strategy. No lan-
guage restriction was used in the literature search. The
search was limited to studies in humans. The literature
was searched from inception until 22 March 2016. Two
reviewers (MCS and PP) evaluated each article inde-
pendently. Disagreements were resolved by discussion
with a third party (MB).
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2.2 Study Selection
Original studies were included if they met the following
inclusion criteria: (1) interventional studies (either with a
parallel or cross-over design), post hoc analyses and
observational studies (either with a prospective or retro-
spective design); (2) inclusion of a control group; (3)
investigating the impact of tamoxifen on plasma/serum
concentrations of Lp(a); and (4) presentation of sufficient
information on Lp(a) concentrations at baseline and at the
end of follow-up in each group or providing the net change
values. Exclusion criteria were (1) lack of an appropriate
control group in the study design and (2) lack of sufficient
information on baseline or follow-up Lp(a) concentrations.
2.3 Data Extraction
Eligible studies were reviewed, and the following data
were abstracted: (1) first author’s name; (2) year of pub-
lication; (3) study location; (4) study design; (5) inclusion
criteria and underlying disease; (6) number of participants
in the statin and control (in case of randomized design)
groups; (7) age, gender and body mass index (BMI) of
study participants; and (8) baseline, follow-up and change
values of plasma Lp(a) concentrations. Data extraction was
performed independently by two reviewers; disagreements
were resolved by a third reviewer. Risk of bias in non-
randomized and observational studies was assessed using
the Risk Of Bias In Non-randomized Studies of Interven-
tions (ROBINS-I) tool [32]. This tool evaluates the risk of
bias across seven domains, including confounding, selec-
tion of participants, classification of interventions, devia-
tion from intended interventions, missing data,
measurement of outcomes or interventions, and selection of
reported results.
2.4 Quality Assessment
A systematic assessment of bias in the included studies was
performed using the Cochrane criteria [33]. The items used
for the assessment of each study were as follows: adequacy
of sequence generation, allocation concealment, blinding,
dropouts addressed (incomplete outcome data), selective
outcome reporting, and other potential sources of bias.
According to the recommendations of the Cochrane hand-
book, a judgment of ‘‘yes’’ indicated low risk of bias, while
‘‘no’’ indicated high risk of bias. Labeling an item as ‘‘un-
clear’’ indicated an unclear or unknown risk of bias. Risk-of-
bias assessment was performed independently by two
reviewers; disagreements were resolved by a third reviewer.
2.5 Quantitative Data Synthesis
Meta-analysis was conducted using Comprehensive Meta-
Analysis (CMA) V2 software (Biostat, NJ) [34]. Net
changes in measurements (change scores) were calculated
as follows: measure at end of follow-up - measure at
baseline. For cross-over trials, net change in plasma con-
centrations of Lp(a) were calculated by subtracting the
value after the control intervention from that reported after
treatment. All values were collated in mg/dL. Standard
deviations (SDs) of the mean difference were calcu-
lated using the following formula: SD = square root
[(SDpre-treatment)
2 ? (SDpost-treatment)
2 - (2R 9 SDpre-treatment 9
SDpost-treatment)], assuming a correlation coefficient
(R) = 0.5. If the outcome measures were reported in
median and interquartile range, mean and SD values were
estimated using the method described by Hozo et al. [35].
To convert interquartile range into minimum–maximum
range, the following equations were used: A = me-
dian ? 2 9 (Q3 - median) and B = median - 2 9 (me-
dian - Q1), where A, B, Q1 and Q3 are upper and lower
ends of the range and upper and lower ends of the
interquartile range, respectively. Where only standard error
of the mean (SEM) was reported, SD was estimated using
the following formula: SD = SEM 9 square root (n),
where n is the number of subjects. When the results were
presented in multiple time points, only data relating to the
longest duration of treatment were considered. In order to
avoid the double-counting problem in trials comparing
multiple treatment arms versus a single control group, the
number of subjects in the control group was divided by the
number of treatment arms. When no SD was provided for
plasma Lp(a) concentrations in a study, the pooled SD of
other studies was used as the substitute. When the data
were not tabulated, but presented only as graphs, the
software GetData Graph Digitizer 2.24 (http://getdata-
graph-digitizer.com/) was applied to digitize and extract
the data.
A random-effects model (using the DerSimonian-Laird
method) and the generic inverse variance method were
used to compensate for the heterogeneity of studies in
terms of demographic characteristics of populations being
studied and also differences in study designs. Hetero-
geneity was quantitatively assessed using the I2 index.
Effect sizes were expressed as standardized mean differ-
ence (SMD) and 95% confidence interval (CI). In order to
evaluate the influence of each study on the overall effect
size, sensitivity analysis was conducted using the leave-
one-out method, i.e., removing one study each time and
repeating the analysis [36–38].
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3 Results
3.1 Flow and Characteristics of Included Studies
The initial screening for potential relevance removed the
articles whose titles and/or abstracts were obviously irrele-
vant. Among the 11 full-text articles assessed for eligibility,
six studies were excluded because of the following reasons:
study was not controlled for tamoxifen (n = 1), duplicate
data report (n = 3), incomplete data (n = 1), not measuring
Lp(a) (n = 1) (Fig. 1). After assessment, five studies met
the inclusion criteria and were included in the meta-analysis
[28, 39–42]. In total, 104 participants were allocated to the
tamoxifen group and 111 to the control group in the selected
studies. The number of participants in these studies ranged
from 17 to 68. Included studies were published between
1994 and 2003, and were conducted in USA (two studies),
Italy, Turkey and the UK. All studies used tamoxifen tablets,
and the administered dosage ranged from 10 mg adminis-
tered on alternate days to 40 mg/day. The duration of
tamoxifen therapy ranged between 56 days and 14 months.
Five studies were designed as randomized parallel-group
trials and one as an observational study. Demographic and
baseline parameters of the included studies are shown in
Table 1. The assessment of risk of bias in the included
studies using Cochrane criteria is shown in Table 2. Most of
the included studies had a low risk of bias with respect to
different criteria specified for the quality assessment. How-
ever, the studies by Decensi et al. [43] and Love et al. [44]
were identified as having a high risk regarding blinding of
participants and personnel and outcome assessment.
3.2 Effect of Tamoxifen on Plasma
Lp(a) Concentrations
The impact of tamoxifen on plasma Lp(a) concentrations
was reported in seven treatment arms. Meta-analysis sug-
gested a significant reduction of Lp(a) levels following
tamoxifen treatment (SMD -0.41, 95% CI -0.68 to -
0.14, p = 0.003; I2 = 0%; Q = 1.97) (Fig. 2). This result
was robust in the sensitivity analysis (Fig. 3). Likewise,
when the studies with higher risk of bias were removed
from the meta-analysis, the effect size remained statisti-
cally significant (SMD -0.49, 95% CI -0.92 to -0.05,
p = 0.027; I2 = 0%; Q = 1.44).
4 Discussion
To our knowledge, this meta-analysis is the first to collate
the evidence obtained from RCTs and observational studies
on the efficacy of supplementation with tamoxifen on
plasma Lp(a) concentrations. The results suggested a sta-
tistically significant reduction of circulating Lp(a) concen-
trations following tamoxifen treatment. Based on a general
rule of thumb, our estimated effect size could be regarded
as a small to medium effect.
Our results are in agreement with the findings of other
studies whose design did not make them eligible for
inclusion in this study. For example, in a study that
included 38 tamoxifen-treated (20 mg/day) post-
menopausal women with breast cancer, Elisaf et al.
observed a statistically significant reduction in median
circulating concentrations of Lp(a) [45]. These methods
and results were very similar to those of a small study
performed by Shewmon et al., where a stable reduction in
Lp(a) was observed after 1 month of tamoxifen therapy in
five out of six study participants with breast cancer [46].
Similar effects have been observed with other SERMS.
In a recent systematic review and meta-analysis of 12
studies with 1009 patients, tibolone was shown to be
effective in decreasing Lp(a) levels in postmenopausal
women [47]. Tibolone has estrogenic, progestogenic, and
weak androgenic actions, and together, the results of these
two meta-analysis suggest that further investigation of
estrogen receptor ligands may be fruitful in the treatment of
elevated Lp(a).
The effects of tamoxifen on lipid metabolism have been
researched in several experimental and clinical studies, but
the exact mechanisms responsible for tamoxifen-lowering
effects on Lp(a) levels are not fully understood. Because
tamoxifen acts as an agonist of estrogen receptors in some
tissues [48, 49], we can look to the effects of estrogen on
the liver and on lipoprotein metabolism to help us under-
stand the effects of tamoxifen. Barton has extensively
reviewed the effects of estrogen on cholesterol and
atherosclerosis [50]. With respect to Lp(a), it has been
demonstrated that hormone replacement therapy (HRT)
with estrogen leads to lower circulating Lp(a) concentra-
tions [51] and that letrozole, an aromatase inhibitor that
reduces endogenous production of estrogen, has the
opposite effect on Lp(a) [52]. Estrogen may mediate its
effects by altering the biosynthesis of Lp(a) and thus
reducing the availability of precursors and component
molecules, in particular apoB-100 and apo(a). Circulating
concentrations of Lp(a) levels are determined to a greater
extent by genetically defined hepatic biosynthesis than by
catabolism [53]; estrogens are known to enhance hepatic
very low-density lipoprotein (VLDL) synthesis and
excretion [4], thus leaving less apoB-100 available for the
biosynthesis of Lp(a). Apo(a) has an interleukin-6 (IL-6)
responsive element in its gene promoter region [54], and
estrogens may regulate apo(a) levels indirectly through
their impact on IL-6 [55], despite the fact that tamoxifen
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was found to be associated with increased apo(a) in one
clinical study [28].
Recent in vitro studies have shed light on potential
mechanisms by which the effect of tamoxifen may be
mediated. Experiments employing primary hepatocytes
[56] and HepG2 hepatocytes [57] supported evidence for
a role of LDL receptors (LDLRs) in the catabolism of
Lp(a). In the same cell type, the SERMS tamoxifen,
raloxifene and toremifene have been shown to up-regulate
LDLR activity [58]. Similar effects of estradiol have been
observed in the rat, leading to up-regulation of hepatic
LDLR and a reduction of LDL [59]. It is not clear
whether the same effects would occur in humans in vivo
at clinically relevant doses of SERMS; however, these
experimental results highlight plausible mechanisms by
which tamoxifen may reduce circulating concentrations of
Lp(a).
Although tamoxifen has a generally favorable safety
profile, long-term use of tamoxifen is associated with
serious side effects, including menopause symptoms,
endometrial cancer, and thromboembolism, which have all
led to controversy regarding its use [60]. Of particular
concern with respect to lipid profiles, tamoxifen has been
shown to increase circulating concentrations of triglyc-
erides [61, 62], which can cause life-threatening acute
pancreatitis [63, 64]. These limitations in the overall
risk:benefit ratio of tamoxifen, in addition to the potential
development of drug resistance and problems associated
with patient compliance, have led to the development of
better tolerated and more effective endocrine agents.
The adverse effects described above are likely to limit
the usefulness of tamoxifen as a clinical modulator of
Lp(a). Nevertheless, the results of this meta-analysis are
important because tamoxifen has been shown to reduce
plasma concentrations of Lp(a), despite the fact that this
lipoprotein is relatively resistant to treatment with other
drugs and diet [8]. Furthermore, Lp(a) may partially
account for residual cardiovascular risk after optimal LDL
reduction with statins [65, 66]. Thus, Lp(a) should be
regarded as a crucial clinical target, and the results of the
present study suggest that estrogen receptor ligands show
promise in this respect. Finally, the widespread use of
tamoxifen and especially its use in the prophylaxis of
breast cancer [67] makes it important that clinicians
understand the cardiovascular effects of such treatment.
The present study adds to our understanding of this issue.
The present meta-analysis has some limitations. There
were only a few eligible RCTs, and most of them had a
modest number of participants. Administered tamoxifen
dose in the included studies was mainly fixed at 20 mg/day,
and this hindered assessment of any dose–response asso-
ciation for the Lp(a)-lowering activity of the drug. Fur-
thermore, the included studies were heterogeneous
concerning the characteristics of patients, study design,
duration and the methods of Lp(a) quantification. Finally, it
remains somewhat unclear whether the calculated Lp(a)-
Fig. 1 Flow chart of the
number of studies identified and
included into the meta-analysis
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lowering effect of tamoxifen can be translated to a clini-
cally relevant cardiovascular risk reduction. Addressing
this uncertainty necessitates additional evidence from
large-scale trials, particularly those performed in subjects
with elevated plasma Lp(a) concentrations at baseline.
5 Conclusion
This meta-analysis suggests a statistically significant
reduction of Lp(a) levels after tamoxifen treatment. Further
well-designed trials are required to validate these results.
Fig. 2 Forest plot detailing standardized mean difference and 95% confidence intervals (CIs) for the impact of tamoxifen on plasma
lipoprotein(a) concentrations (I2 = 0%; Q = 1.97, p = 0.741)
Table 2 Assessment of risk of bias in the included studies using Cochrane criteria
Study Sequence
generation
Allocation
concealment
Blinding of
participants and
personnel
Blinding of outcome
assessment
Incomplete
outcome
data
Selective
outcome
reporting
Other potential
threats to validity
Decensi
et al. 1998
[39]
U U H H L L L
Clarke et al.
2001 [40]
L L L L L L L
Love et al.
1994 [28]
L L H H L L L
Shewmon
et al. 1994
[42]
U U L L L L L
Bias due to
confounding
Bias in
participant
selection
Bias in
classification of
interventions
Bias due to departures
from intended
interventions
Bias due to
missing
data
Bias in
measurement
of outcomes
Bias in selection
of the reported
result
Genc¸ et al.
2003
[41]a
L L L L L L L
Risk of bias assessment according to the Cochrane Collaboration’s tool for randomized controlled trials and ROBINS-I tool for non-randomized
and observational studies
H high risk of bias, L low risk of bias, ROBINS-I Risk Of Bias In Non-randomized Studies of Interventions, U unclear risk of bias
a Study had an observational design
Fig. 3 Leave-one-out sensitivity analysis of the meta-analysis of tamoxifen’s effects on plasma lipoprotein(a) concentrations. Sensitivity
analysis was performed by iterative removal of each study and repeating the analysis. CI confidence interval
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